INBX Soars 81% Post-Study; FEMY, CING, CYH Pop After Hours

Core Insights - Biotech stocks experienced significant gains in after-hours trading, with Inhibrx Biosciences leading the surge due to positive trial results [1][2] Company Summaries - Inhibrx Biosciences (INBX): Shares surged over 81% to $51.52 following positive topline results from the ChonDRAgon study, which evaluated ozekibart as a monotherapy for advanced chondrosarcoma. The company also reported progress on expansion cohorts for colorectal cancer and Ewing sarcoma [2] - Femasys Inc. (FEMY): Stock increased by more than 18% to $0.7227 after launching a post-market surveillance clinical study for its FemBloc Permanent Birth Control, complying with EU Medical Device Regulation [3] - Cingulate Inc. (CING): Shares rose over 6% to $3.80 after announcing that data from its ADHD candidate CTx-1301 was selected for presentation at the AACAP Annual Meeting, highlighting its potential in ADHD treatment [4] - Community Health Systems, Inc. (CYH): Stock increased over 4% to $3.41 following positive Q3 results [5] - Reviva Pharmaceuticals Holdings Inc. (RVPH): Shares climbed over 10% to $0.6295 in after-hours trading [6] - Ascendis Pharma A/S (ASND): Stock gained more than 4%, reaching $210.68 post-market [6] - ADC Therapeutics SA (ADCT): Shares rose over 5% to $4.2887 in after-hours trading [6] - Zura Bio Limited (ZURA): Stock increased more than 5% to $3.55 post-market [6] - Foghorn Therapeutics Inc. (FHTX): Shares gained more than 5%, closing at $4.11 after hours [6]